Lynn Morris to Anti-HIV Agents
This is a "connection" page, showing publications Lynn Morris has written about Anti-HIV Agents.
Connection Strength
2,632
-
HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. PLoS One. 2020; 15(6):e0234937.
Score: 0,369
-
Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther. 2013; 18(7):915-20.
Score: 0,227
-
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17; 24(11):1679-87.
Score: 0,185
-
HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008 Nov; 24(11):1449-54.
Score: 0,165
-
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006 Apr 24; 20(7):995-1002.
Score: 0,138
-
Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4-8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011-12 and 2012-13. BMC Infect Dis. 2019 Sep 16; 19(Suppl 1):787.
Score: 0,088
-
Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods. Antivir Ther. 2019; 24(3):203-210.
Score: 0,083
-
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018 11; 18(11):1241-1250.
Score: 0,082
-
Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017 Nov 01; 72(11):3141-3148.
Score: 0,077
-
Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infect Dis. 2015 Jul; 15(7):803-9.
Score: 0,065
-
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015 Apr; 12(4):e1001810.
Score: 0,064
-
Novel indole based NNRTIs with improved potency against wild type and resistant HIV. Bioorg Med Chem Lett. 2014 Sep 15; 24(18):4376-4380.
Score: 0,061
-
Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. J Infect Dev Ctries. 2014 Jul 14; 8(7):845-52.
Score: 0,061
-
Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. Trop Med Int Health. 2014 Feb; 19(2):236-9.
Score: 0,059
-
Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial. J Infect Dis. 2014 Jun 15; 209(12):1916-20.
Score: 0,059
-
Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014 Mar 01; 209(5):711-20.
Score: 0,057
-
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
Score: 0,052
-
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):304-8.
Score: 0,051
-
Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS One. 2011; 6(6):e21450.
Score: 0,050
-
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010 Sep 08; 304(10):1082-90.
Score: 0,047
-
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 03; 329(5996):1168-74.
Score: 0,046
-
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009 Dec 15; 49(12):1928-35.
Score: 0,045
-
Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS. 2009 Apr 27; 23(7):809-16.
Score: 0,043
-
Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. Antimicrob Agents Chemother. 2009 Jul; 53(7):3056-64.
Score: 0,042
-
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15; 48(4):462-72.
Score: 0,042
-
Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2008 Dec 15; 49(5):538-43.
Score: 0,042
-
Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS. 2008 Jul 11; 22(11):1333-43.
Score: 0,040
-
Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 2007 Jun 01; 45(2):206-9.
Score: 0,037
-
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2007 Feb 01; 44(2):148-53.
Score: 0,036
-
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005 Jul 01; 192(1):16-23.
Score: 0,032
-
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol. 2003 Apr; 77(7):4449-56.
Score: 0,028
-
HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. AIDS Res Hum Retroviruses. 2002 May 20; 18(8):605-10.
Score: 0,026
-
The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin a4ß7 and promotes cellular activation and infection. Proc Natl Acad Sci U S A. 2020 12 22; 117(51):32566-32573.
Score: 0,024
-
Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. BMJ Open. 2019 07 03; 9(7):e030283.
Score: 0,022
-
Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant. Antivir Ther. 2019; 24(5):333-342.
Score: 0,021
-
HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host Microbe. 2018 10 10; 24(4):593-599.e3.
Score: 0,020
-
Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS. 2014 Jul 17; 28(11):1673-8.
Score: 0,015
-
Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis. 2011 Mar 15; 203(6):798-802.
Score: 0,012
-
A model of directional selection applied to the evolution of drug resistance in HIV-1. Mol Biol Evol. 2007 Apr; 24(4):1025-31.
Score: 0,009
-
Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. J Virol Methods. 2005 May; 125(2):99-109.
Score: 0,008